RSPO3 binding agents and uses thereof
The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO3 proteins and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
1. An isolated monoclonal antibody that specifically binds human R-spondin 3 (RSPO3), which comprises:
(a) a heavy chain CDR1 comprising KASGYTFTDYS (SEQ ID NO:9), KASGYTFTSYTF (SEQ ID NO:34), or DYSIH (SEQ ID NO:78), a heavy chain CDR2 comprising IYPSNGDS (SEQ ID NO:10) or YIYPSNGDSGYNQKFK (SEQ ID NO:79), and a heavy chain CDR3 comprising ATYFANYFDY (SEQ ID NO:11), ATYFANNFDY (SEQ ID NO:35), or TYFANNFD (SEQ ID NO:80); and
(b) a light chain CDR1 comprising QSVDYDGDSYM (SEQ ID NO:12) or KASQSVDYDGDSYMN (SEQ ID NO:81), a light chain CDR2 comprising AAS (SEQ ID NO:13) or AASNLES (SEQ ID NO:82), and a light chain CDR3 comprising QQSNEDPLT (SEQ ID NO:14) or QQSNEDPLTF (SEQ ID NO:83).
2. The antibody of claim 1 , which comprises:
(a) a heavy chain CDR1 comprising KASGYTFTDYS (SEQ ID NO:9), a heavy chain CDR2 comprising IYPSNGDS (SEQ ID NO:10), and a heavy chain CDR3 comprising TYFANNFD (SEQ ID NO:80); and
(b) a light chain CDR1 comprising QSVDYDGDSYM (SEQ ID NO:12), a light chain CDR2 comprising AAS (SEQ ID NO:13), and a light chain CDR3 comprising QQSNEDPLT (SEQ ID NO:14).
3. The antibody of claim 1 , which comprises:
(a) a heavy chain variable region having at least 90% sequence identity to SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:44, SEQ ID NO:45, or SEQ ID NO:62; and
(b) a light chain variable region having at least 90% sequence identity to SEQ ID NO:17, SEQ ID NO:72, or SEQ ID NO:86.
4. An isolated monoclonal antibody that specifically binds human RSPO3, which comprises:
(a) a heavy chain variable region comprising SEQ ID NO:15 and a light chain variable region comprising SEQ ID NO:17 or SEQ ID NO:72;
(b) a heavy chain variable region comprising SEQ ID NO:16 and a light chain variable region comprising SEQ ID NO:17 or SEQ ID NO:72;
(c) a heavy chain variable region comprising SEQ ID NO:36 and a light chain variable region comprising SEQ ID NO:17 or SEQ ID NO:72;
(d) a heavy chain variable region comprising SEQ ID NO:37 and a light chain variable region comprising SEQ ID NO:17 or SEQ ID NO:72;
(e) a heavy chain variable region comprising SEQ ID NO:44 and a light chain variable region comprising SEQ ID NO:17, SEQ ID NO:72, or SEQ ID NO:86;
(f) a heavy chain variable region comprising SEQ ID NO:45 and a light chain variable region comprising SEQ ID NO:17, SEQ ID NO:72, or SEQ ID NO:86; or
(g) a heavy chain variable region comprising SEQ ID NO:62 and a light chain variable region comprising SEQ ID NO:17, SEQ ID NO:72, or SEQ ID NO:86.
5. The antibody of claim 1 , which is a recombinant antibody, a chimeric antibody, a bispecific antibody, a humanized antibody, an IgG1 antibody, an IgG2 antibody, or an antibody fragment comprising an antigen binding site.
6. An isolated monoclonal antibody comprising:
(a) a heavy chain sequence of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:64, or SEQ ID NO:69; and
(b) a light chain sequence of SEQ ID NO:29, SEQ ID NO:74, or SEQ ID NO:88.
7. The antibody of claim 6 , which comprises:
(a) a heavy chain sequence of SEQ ID NO:48 and a light chain sequence of SEQ ID NO:74 or SEQ ID NO:88;
(b) a heavy chain sequence of SEQ ID NO:64 and a light chain sequence of SEQ ID NO:74 or SEQ ID NO:88; or
(c) a heavy chain sequence of SEQ ID NO:69 and a light chain sequence of SEQ ID NO:74 or SEQ ID NO:88.
8. An isolated monoclonal antibody comprising the heavy chain variable region encoded by the plasmid deposited with ATCC as PTA-120420 and the light chain variable region encoded by the plasmid deposited with ATCC as PTA-120421.
9. An isolated polypeptide comprising a sequence selected from the group consisting of: SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64 SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:86, SEQ ID NO:87, and SEQ ID NO:88.
10. A cell comprising or producing the antibody of claim 1 .
11. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
12. The antibody of claim 1 , which comprises:
(a) a heavy chain CDR1 comprising DYSIH (SEQ ID NO:78), a heavy chain CDR2 comprising YIYPSNGDSGYNQKFK (SEQ ID NO:79), and a heavy chain CDR3 comprising TYFANNFD (SEQ ID NO:80); and
(b) a light chain CDR1 comprising KASQSVDYDGDSYMN (SEQ ID NO:81), a light chain CDR2 comprising AASNLES (SEQ ID NO:82), and a light chain CDR3 comprising QQSNEDPLT (SEQ ID NO:14).
13. The antibody of claim 12 , which is a recombinant antibody, a chimeric antibody, a bispecific antibody, a humanized antibody, an IgG1 antibody, an IgG2 antibody, or an antibody fragment comprising an antigen binding site.
14. A pharmaceutical composition comprising the antibody of claim 12 and a pharmaceutically acceptable carrier.
15. An isolated monoclonal antibody that specifically binds human RSPO3, which comprises a heavy chain variable region comprising SEQ ID NO:44 and a light chain variable region comprising SEQ ID NO:86.